Literature DB >> 12439928

ROC curves in evaluation of serum fibrosis indices for hepatic fibrosis.

Min Zheng1, Wei-Min Cai, Hong-Lei Weng, Rong-Hua Liu.   

Abstract

AIM: Use Receiver operating characteristic (ROC) curves to find out the relationship between serum level of hyaluronic acid (HA), type III procollagen (PCIII), N-terminal procollagen III peptide (PIIINP), laminin (LN), type IV collagen (C-IV) and hepatic fibrosis, as well as to determine their value in clinical practice.
METHODS: 114 serum samples from chronic hepatitis patients were assayed for fibrosis indices including HA, PCIII, PIIINP, LN and IV-C with radioimmunoassay (RIA). Liver biopsy was also performed in all these patients and the biopsy material was examined histopathologically.
RESULTS: ROC curves analysis showed that area under the curve (AUC) of PIIINP, HA, PCIII, C-IV and LN was 0.800, 0.728, 0.727, 0.583 and 0.463, respectively. The analysis also showed that PIIINP (r=0.452), HA (r=0.497) and PCIII (r=0.404) have greater diagnosis performances than C-IV(r=0.238) and LN (r=0.128) according to fibrosis staging. The sensitivity of HA plus PIIINP was 55.1 %, it was the most sensitive combination. Combined three or more than three indices that based on HA, the specificity was 100 %. Using combination assays can improve the specificity, but its sensitivity was not high. Serum fibrosis indices increased as the grade of inflammation aggravated. But only PIIINP and PCIII had significant difference between G1 and G2 (PIIINP: 13.16+/-8.07 vs 8.32+/-5.09; PCIII: 164.22+/-65.69 vs 138.23+/-77.63). The coefficient correlation of the results of inflammation grade and fibrosis staging to HA was 0.525 and 0.553 respectively, that to PCIII, 0.446 and 0.412, that to LN, 0.234 and 0.194, and that to IV-C, 0.363 and 0.351, respectively.
CONCLUSION: Serum fibrosis indices can indicate tendency of hepatic fibrosis, but it cannot replace liver biopsy. However, as diagnostic markers, more efficient serum fibrosis indices for the diagnosis of hepatic fibrosis need to be explored.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12439928      PMCID: PMC4656383          DOI: 10.3748/wjg.v8.i6.1073

Source DB:  PubMed          Journal:  World J Gastroenterol        ISSN: 1007-9327            Impact factor:   5.742


  30 in total

1.  [Relationship between serum fibrosis markers and fibrosis quantitative analysis of liver tissue].

Authors:  S Gu; H Zhang; L Zhang
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  1999-12

2.  Pancreatic stellate cells are activated by proinflammatory cytokines: implications for pancreatic fibrogenesis.

Authors:  M V Apte; P S Haber; S J Darby; S C Rodgers; G W McCaughan; M A Korsten; R C Pirola; J S Wilson
Journal:  Gut       Date:  1999-04       Impact factor: 23.059

3.  [Three-dimensional reconstruction of experimental fibrotic liver tissue and effect of herbal compound on it].

Authors:  F Zhang; B Wang; T Wang; J Jia; Z Dong; J Zhang
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2000-12

4.  [The relationship between the levels of serum fibrosis marks and morphometric quantitative measurement of hepatic histological fibrosis].

Authors:  S Xie; J Yao; S Zheng; C Yao; R Zheng
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2000-08

5.  Clinical implication of VEGF serum levels in cirrhotic patients with or without portal hypertension.

Authors:  Nimer Assy; M Paizi; D Gaitini; Y Baruch; G Spira
Journal:  World J Gastroenterol       Date:  1999-08       Impact factor: 5.742

6.  [Serum markers and pathological evaluation in hepatitis fibrosis of chronic hepatitis B treated with interferon alpha].

Authors:  L Deng; Y Zhou; X Peng; H Deng; Y Deng; J Yao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2001-07

7.  Noninvasive diagnosis of hepatic fibrosis or cirrhosis.

Authors:  F Oberti; E Valsesia; C Pilette; M C Rousselet; P Bedossa; C Aubé; Y Gallois; H Rifflet; M Y Maïga; D Penneau-Fontbonne; P Calès
Journal:  Gastroenterology       Date:  1997-11       Impact factor: 22.682

8.  Quantitative analysis of transforming growth factor beta 1 mRNA in patients with alcoholic liver disease.

Authors:  Wei-Xing Chen; You-Ming Li; Chao-Hui Yu; Wei-Min Cai; Min Zheng; Feng Chen
Journal:  World J Gastroenterol       Date:  2002-04       Impact factor: 5.742

9.  [A preliminary study of the combination of noninvasive parameters in the diagnosis of liver fibrosis].

Authors:  C Li; M Wan; M Zeng; B Su; Q He; L Lu; Y Mao
Journal:  Zhonghua Gan Zang Bing Za Zhi       Date:  2001-10

10.  Mechanisms of spontaneous resolution of rat liver fibrosis. Hepatic stellate cell apoptosis and reduced hepatic expression of metalloproteinase inhibitors.

Authors:  J P Iredale; R C Benyon; J Pickering; M McCullen; M Northrop; S Pawley; C Hovell; M J Arthur
Journal:  J Clin Invest       Date:  1998-08-01       Impact factor: 14.808

View more
  17 in total

1.  Diagnostic accuracy of serum biochemical fibrosis markers in children with chronic hepatitis B evaluated by receiver operating characteristics analysis.

Authors:  Dariusz Marek Lebensztejn; Elzbieta Skiba; Jolanta Tobolczyk; Maria Elzbieta Sobaniec-Lotowska; Maciej Kaczmarski
Journal:  World J Gastroenterol       Date:  2005-12-07       Impact factor: 5.742

2.  Sampling variability of computer-aided fractal-corrected measures of liver fibrosis in needle biopsy specimens.

Authors:  Fabio Grizzi; Carlo Russo; Barbara Franceschini; Mariagrazia Di Rocco; Valter Torri; Emanuela Morenghi; Luigi Rainiero Fassati; Nicola Dioguardi
Journal:  World J Gastroenterol       Date:  2006-12-21       Impact factor: 5.742

Review 3.  Capillaria hepatica in China.

Authors:  Chao-Ding Li; Hui-Lin Yang; Ying Wang
Journal:  World J Gastroenterol       Date:  2010-02-14       Impact factor: 5.742

4.  Matrix-derived serum markers in monitoring liver fibrosis in children with chronic hepatitis B treated with interferon alpha.

Authors:  Dariusz-Marek Lebensztejn; Maria-Elzbieta Sobaniec-Lotowska; Maciej Kaczmarski; Michael Voelker; Detlef Schuppan
Journal:  World J Gastroenterol       Date:  2006-06-07       Impact factor: 5.742

5.  Noninvasive evaluation of hepatic fibrosis in children with infant hepatitis syndrome.

Authors:  Zhi-Xian Li; Yun He; Ji Wu; Dan-Mei Liang; Bu-Lin Zhang; Hong Yang; Ling-Ling Wang; Yun Ma; Kang-Lai Wei
Journal:  World J Gastroenterol       Date:  2006-11-28       Impact factor: 5.742

6.  Low plasma apolipoprotein A-I level is not a reliable marker of fibrosis in children with chronic hepatitis B.

Authors:  Mukadder-Ayse Selimoglu; Rasit-Vural Yagcl; Gül Yüce
Journal:  World J Gastroenterol       Date:  2004-10-01       Impact factor: 5.742

7.  Relationship between clinical and pathologic findings in patients with chronic liver diseases.

Authors:  Lun-Gen Lu; Min-De Zeng; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Jing-Yuan Fang; Ai-Ping Cao; Mo-Bin Wan; Cheng-Zhong Li; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-12       Impact factor: 5.742

8.  Influence factors of serum fibrosis markers in liver fibrosis.

Authors:  Jun Tao; Hui-Qin Peng; Wei-Min Cai; Feng-Qin Dong; Hong-Lei Weng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

9.  Grading and staging of hepatic fibrosis, and its relationship with noninvasive diagnostic parameters.

Authors:  Lun-Gen Lu; Min-De Zeng; Mo-Bin Wan; Cheng-Zhong Li; Yi-Min Mao; Ji-Qiang Li; De-Kai Qiu; Ai-Ping Cao; Jun Ye; Xiong Cai; Cheng-Wei Chen; Ji-Yao Wang; Shan-Ming Wu; Jin-Shui Zhu; Xia-Qiu Zhou
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

10.  Diagnostic value of platelet derived growth factor-BB, transforming growth factor-beta1, matrix metalloproteinase-1, and tissue inhibitor of matrix metalloproteinase-1 in serum and peripheral blood mononuclear cells for hepatic fibrosis.

Authors:  Bin-Bin Zhang; Wei-Min Cai; Hong-Lei Weng; Zhong-Rong Hu; Jun Lu; Min Zheng; Rong-Hua Liu
Journal:  World J Gastroenterol       Date:  2003-11       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.